Apnimed, Inc. Common Stock (APMD) - Total Liabilities
Based on the latest financial reports, Apnimed, Inc. Common Stock (APMD) has total liabilities worth $85.04 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Apnimed, Inc. Common Stock defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Apnimed, Inc. Common Stock - Total Liabilities Trend (2024–2025)
This chart illustrates how Apnimed, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See Apnimed, Inc. Common Stock (APMD) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Apnimed, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Apnimed, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shandong Ruifeng Chemical Co Ltd
SHE:300243
|
China | CN¥1.18 Billion |
|
Ocean’s King Lighting Science & Technology Co Ltd
SHE:002724
|
China | CN¥627.08 Million |
|
Shanxi Zhendong Pharmaceutical
SHE:300158
|
China | CN¥882.65 Million |
|
Senvest Capital Inc.
TO:SEC
|
Canada | CA$3.96 Billion |
|
Criteo Sa
NASDAQ:CRTO
|
USA | $846.65 Million |
|
Diversified United Investment Ltd
AU:DUI
|
Australia | AU$292.18 Million |
|
Grupo Posadas S.A.B. de C.V
MX:POSADASA
|
Mexico | MX$17.92 Billion |
|
Tianjin Printronics Circuit Corp
SHE:002134
|
China | CN¥1.57 Billion |
Liability Composition Analysis (2024–2025)
This chart breaks down Apnimed, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see APMD current and non-current assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Apnimed, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Apnimed, Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of Apnimed, Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $445.66 Million | +24.54% |
| 2024-12-31 | $357.84 Million | -- |
About Apnimed, Inc. Common Stock
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambr… Read more